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Autoimmune-prone mice share a promoter haplotype associated
with reduced expression and function of the Fc receptor FcγRII
Nicholas R. Pritchard*, Antony J. Cutler*, Santiago Uribe†, Steven J. Chadban*,
Bernard J. Morley† and Kenneth G.C. Smith*
Human autoimmune diseases thought to arise from
the combined effects of multiple susceptibility genes
include systemic lupus erythematosus (SLE) and
autoimmune diabetes. Well-characterised polygenic
mouse models closely resembling each of these
diseases exist, and genetic evidence links receptors
for the Fc portion of immunoglobulin G (FcR) with
their pathogenesis in mice and humans [1–3]. FcRs
may be activatory or inhibitory and regulate a
variety of immune and inflammatory processes [4,5].
FcγRII (CD32) negatively regulates activation of
cells including B cells and macrophages [6].
FcγRII-deficient mice are prone to immune-mediated
disease [7–9]. The gene encoding FcγRII, Fcgr2, is
contained in genetic susceptibility intervals in mouse
models of SLE such as the New Zealand Black (NZB)
contribution to the (NZB × New Zealand White (NZW))
F1 strain [1,10,11] and the BXSB strain [12], and in
human SLE [1–3]. We therefore sequenced Fcgr2 and
identified a haplotype defined by deletions in the
Fcgr2 promoter region that is present in major
SLE-prone mouse strains (NZB, BXSB, SB/Le, MRL,
129 [13]) and non-obese diabetic (NOD) mice but
absent in control strains (BALB/c, C57BL/6, DBA/2,
C57BL/10) and NZW mice. The autoimmune
haplotype was associated with reduced cell-surface
expression of FcγRII on macrophages and activated
B cells and with hyperactive macrophages resembling
those of FcγRII-deficient mice, and is therefore likely
to play an important role in the pathogenesis of SLE
and possibly diabetes.
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Results and discussion
Identical deletions in the promoter of Fcgr2 are common to
major mouse models of autoimmune disease
We sequenced 2,000 bp of the putative promoter region.
The major SLE-prone mouse strains (NZB, BXSB, SB/Le
and MRL) and NOD mice all shared a common Fcgr2 hap-
lotype, characterised by a number of promoter alterations
largely confined to the 250 bp immediately upstream of
the start codon, and previously described in the NOD
mouse [14]. The major one was a 13 bp deletion interrupt-
ing two putative transcription factor binding sites, an AP4
site and an S box (Figure 1 and see Supplementary mater-
ial). Control strains shared the ‘normal’ haplotype, and the
NZW mouse had features of both (Figure 1). The 129/Sv
(and 129/Ola) mice are also prone to autoimmunity. For
example, Lyn–/– mice made on the 129 background have
substantially worse autoimmune disease than when they
are backcrossed to C57BL/6 or BALB/c backgrounds
(D.M. Tarlinton, personal communication) and the 129
background makes a contribution to the development of
disease in the C1q–/– mouse (M. Botto, personal communi-
cation). We have termed this constellation of Fcgr2 pro-
moter polymorphisms the ‘autoimmune Fcgr2 promoter
haplotype’ (AIH). AIH strains include NZB, BXSB,
SB/Le, MRL, NOD and 129.
Figure 1
Sequence of the Fcgr2 promoter from autoimmune and control mouse
strains. Control strains (con) include BALB/c, C57BL/6, C57BL/10
and DBA/2. AIH strains include NZB, BXSB, MRL, SB/Le, 129/Ola,
129/Sv and NOD. NZW mice share elements of both haplotypes. A
dash indicates no difference from the control sequence and asterisks
indicate deleted nucleotides. Nucleotides are numbered relative to the
transcriptional start site (+1). Transcribed sequences are upper case.
Consensus sequences for transcription factors are boxed and
discussed further in the Supplementary material. 
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The AIH is associated with reduced expression of FcγRII on
macrophages and activated B cells
FcγRII expression was examined to determine if there was
a defect associated with the AIH. There are two isoforms
of FcγRII expressed on the cell surface in mice, FcγRIIb1
on B cells and FcγRIIb2 on cells including monocytes,
macrophages, and mast cells [4,5]. Peritoneal macrophages
were stained with monoclonal antibody 2.4G2 (which
recognises the identical extracellular domains of both
FcγRIIb2 and FcγRIII on these cells [15]). FcγRII/III
levels on all AIH strains were reduced in comparison to
control strains and NZW mice, and (NZB × NZW) F1 mice
expressed intermediate levels (Figure 2a). Levels of
FcγRIIb1 (the only FcR recognised by 2.4G2 on B cells)
were similar on resting splenic B cells of all of the strains
studied, but fell progressively over time after activation
in vitro in strains with the AIH (Figure 2b,d). To confirm
that the reduction in 2.4G2 staining seen on AIH strain
macrophages was due to a reduction in FcγRII rather than
FcγRIII, reduced expression of FcγRII was demonstrated
by measuring mRNA specific for the various FcγRII iso-
forms using real-time RT–PCR. There was a marked
reduction of Fcgr2 mRNA in AIH strain macrophages. No
such reduction was seen in Fcgr3 mRNA, and the ratio of
Fcgr3 to Fcgr2 mRNA was consistently increased in AIH
strains (Figure 3a). Fcgr2 mRNA was present in normal
levels in the resting B cells of both control and AIH strains
(data not shown) but was reduced in activated B cells from
AIH strains (Figure 3b), consistent with the reduction in
expression of surface FcγRII protein (Figure 2b,d).
Further confirmation of the reduction in FcγRII expres-
sion on macrophages was obtained at the protein level
(Figure 3c). A marked reduction in FcγRIIb2 was seen in
NZB macrophages compared to control, particularly when
assessed relative to FcγRIII. Thus, the observed reduction
in 2.4G2 staining on macrophages is due to a reduction in
FcγRIIb2, and the increase in the ratio of FcγRIII to
FcγRII explains the functional effects outlined below.
Failure of FcγRII-mediated negative regulation results in
macrophage hyperactivity in AIH mice
To determine if the reduced expression of FcγRII in AIH
mice has functional consequences, we measured the
ability of macrophages to engulf opsonised sheep red
blood cells (SRBCs). The cells were first haptenated with
trinitrophenol (TNP) and then specific mouse anti-TNP
antibodies were bound to opsonise the SRBCs by coating
them with mouse antibody. The process of phagocytosis is
dependent on activatory FcRs such as FcγRIII, and inhib-
ited by FcγRII. Enhanced phagocytosis was seen in all
mice carrying the AIH (Figure 4), as it had been in
FcγRII-deficient mice [9]. Another measure of macrophage
activation is the increase in intracellular calcium that
follows cross-linking of FcγRIII on macrophages, which is
exaggerated in the macrophages of mice deficient in
FcγRII [9]. FcγRs of purified peritoneal macrophages were
cross-linked with immune complexes and the resulting
intracellular calcium increase was greater in AIH mice than
in controls (Figure 5), to a degree comparable to that seen
in FcγRII–/– mice [9].
SLE in both humans and lupus-prone mouse strains is
associated with polyclonally hyperactive B cells and
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Figure 2
Reduction in FcγRII expression on macrophages and activated B cells.
(a) Flow cytometric profiles of expression of 2.4G2 (which detects both
FcγRII and FcγRIII on macrophages) on peritoneal macrophages of
C57BL/6, NZB and NOD mice (upper panel), and NZB, NZW and
(NZB × NZW)F1 mice (lower panel). The left-hand curves on each
graph are isotype controls. Macrophages (Mac-1+, B220–; for gating
see the Supplementary material) had similar frequency, scatter
characteristics and levels of Mac-1 expression in AIH mice as in control
mice. (b) FcγRII expression compared to isotype controls (left curves)
on resting B cells (0 h), B cells cultured for 72 h in the presence of IL-4
(unstimulated) and B cells stimulated for 24 h and 72 h with anti-
immunoglobulin M (IgM) F(ab′)2 and IL-4, in NZB and C57BL/6 mice
(F(ab′)2 fragments can bind antigen, but lack the Fc portion and
therefore cannot recruit FcRs). The data are representative of five
separate experiments. The differences observed were not due to
increased activation of AIH B cells relative to controls; surviving cell
numbers, scatter characteristics, expression of activation markers and
cell division controls using 5- and 6-carboxyfluorescein diacetate
succinimidyl ester (CFSE) are shown in the Supplementary material.
(c) Mean channel fluorescence values are shown for three consecutive
experiments identical to that shown in (a). Each value is derived from a
pool of two mice. Reduced staining with 2.4G2 is consistently seen in
all mice with the AIH. (d) Mean channel fluorescence values for 2.4G2
staining are shown for a further two consecutive experiments identical
to that shown in (b) with anti-IgM and IL-4 stimulation for 72 h. Each
value is derived from a pool of two mice.
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enhanced immunoglobulin production [13,16], consis-
tent with a defect in negative regulation of these cells.
Furthermore, targeted deletion of molecules involved in
this negative regulation such as Lyn, CD22, FcγRII,
SHP-1 and PD-1 predisposes to autoimmune disease in
mice [16–18]. Fcgr2 has been identified as a major candi-
date gene in different polygenic mouse models as well as
in humans with SLE [1–3]. Our finding that autoim-
mune-prone mice share a promoter haplotype associated
with reduced expression and function of FcγRII strongly
suggests that this defect plays a role in the pathogenesis
of autoimmune disease. That this haplotype occurs in all
the independently derived major mouse models of SLE
and the NOD mouse model of diabetes, and not in
control mice, suggests the defect in FcγRII makes a pro-
found contribution to the breakdown of tolerance. Other
susceptibility genes that differ between the strains pre-
sumably lead to manifestation of this tolerance defect as
distinct diseases.
SLE is considered an antibody-mediated disease in which
much of the tissue damage is initiated by the deposition of
immune complexes [13]. In such a disease, a defect in neg-
ative regulation of B cells may increase immune complex
production. A similar defect in macrophages might
increase the inflammatory response to these complexes,
and perhaps also antigen presentation, thus contributing
to the pathogenesis of disease. In contrast, diabetes in
the NOD mouse is thought to be a T-cell-mediated
disease. Nonetheless, B cells [19] and macrophages [20]
are also required for the development of diabetes, raising
the possibility that FcγRII might contribute to its patho-
genesis despite being distal to the diabetes susceptibility
locus on chromosome 1 [21].
Similarities in phenotype between the AIH strains might be
due to their sharing the FcγRII defect. NZB mice develop
haemolytic anaemia and contribute to the development of
SLE in the (NZB × NZW) F1 model [13]. Although the
major manifestation of autoimmunity in NOD mice is dia-
betes, they also develop haemolytic anaemia with age [22]
and an SLE-like illness can be induced by immunisation
with mycobacteria [23], suggesting a phenotypic overlap
between NOD and NZB mice that may be due to their
sharing a defect in FcγRII expression. In fact, it has
recently been shown that the development of autoanti-
bodies after microbacterial immunisation in NOD mice is
linked to a susceptibility interval on distal chromosome 1
similar to those in NZB [10,11] and BXSB mice [12] (A.G.
Baxter, personal communication). These similarities in
phenotype might be analogous to ‘overlap’ syndromes seen
in polygenic autoimmune diseases in humans (for example,
mixed connective tissue disease), in which shared suscepti-
bility genes contribute to similarities in disease phenotype
while others contribute to distinct features.
In summary, we have found that the major mouse models of
both SLE and diabetes share a Fcgr2 promoter haplotype.
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Figure 3
Reduction in FcγRII mRNA and protein in
AIH macrophages and activated B cells.
(a) Semi-quantitative analysis of Fgcr2 and
Fgcr3 mRNA levels in macrophages of AIH
and control mice. Macrophages were
purified by flow cytometric sorting, cDNA
made and RT–PCR performed using
primers specific for Fgcr2 and Fgcr3, with
mRNA levels normalised to GAPDH.
Levels are shown relative to BALB/c, and
the ratio between Fgcr3 and Fgcr2 is
shown above. (b) Similar analysis of Fgcr2
mRNA expression in purified B cells
activated for 72 h by anti-immunoglobulin
M (IgM) F(ab′)2 and IL-4. A representative
experiment of (a) four and (b) two is
shown. (c) FcγRII protein levels. Peritoneal
macrophages were surface-iodinated,
lysed and immunoprecipitated with
2.4G2 or isotype control. After
deglycosylation, FcγRII and FcγRIII were
resolved by SDS–PAGE.
Figure 4
Increased phagocytosis of opsonised SRBCs by AIH macrophages.
SRBCs were opsonised, incubated with adherent macrophages, and
the number of phagocytosed SRBCs counted. The graph shows the
number of SRBCs phagocytosed by 250 macrophages of various
strains in four consecutive experiments each using cells pooled from
two mice per strain (Exp, experiment). See also Supplementary material.
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This haplotype is associated with a reduction in the
expression and function of the inhibitory FcγRII on
macrophages and activated B cells, defects which would
be expected to make a substantial contribution to disease
pathogenesis. That the haplotype has been selected in
these independently derived mouse strains suggests that a
defect in FcγRII makes a fundamental contribution to the
development of autoimmune disease, with differences
between the strains determined by other susceptibility
genes, and similarities providing an analogy for auto-
immune ‘overlap’ syndromes.
Supplementary material
Supplementary material including details of transcription factor
binding sites in the Fcgr2 regulatory sequences, the procedure used
to identify B cells and macrophages, control experiments showing that
the differences between AIH control mice are not due to different
levels of activation or proliferation, micrographs of phagocytosis and
additional methodological details is available at http://current-
biology.com/supmat/supmatin.htm.
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Figure 5
Changes in intracellular Ca2+ in peritoneal macrophages from AIH
and control mice. Peritoneal macrophages were purified by adherence,
loaded with the Ca2+ indicator Indo-1 and FcγRs crosslinked with
immune complexes. Changes in FL4/FL5 ratio of the cells was
measured by flow cytometry before and after the addition of immune
complexes at the point indicated by the arrow. Clear differences in
calcium flux are seen between AIH and control mice following
addition of (a) immune complexes, but not with the positive controls
(b) ionomycin and (c) thapsigargin. Ionomycin permeabilises cell
membranes to Ca2+ and thapsigargin releases Ca2+ from intracellular
stores by inhibiting the endoplasmic reticulum Ca2+ ATPase,
producing FcR-independent Ca2+ flux. Representative of three
experiments, with peritoneal macrophages of two or three mice of
each strain pooled in each.
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